PHarmaceutical tech@2x
Diseases Immunology

Sections

  • Clinical Trials
  • Supply Chain
  • Drug Development
  • Manufacturing
  • Diseases
    • Cardiovascular
    • Central Nervous System
    • Immunology
    • Infectious Diseases
    • Oncology
    • Respiratory

Most Read

  • AstraZeneca to acquire biopharmaceutical firm Alexion for $39bn
  • The rise of gout: examining drug development for an age-old disease
  • Sanofi signs agreement to acquire Kiadis Pharma for $359m

Most Recent

deal

AstraZeneca to acquire biopharmaceutical firm Alexion for $39bn

14 Dec 2020
Menu
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Investment
  • Sectors
    • Clinical Trials
    • Supply Chain
    • Drug Development
    • Manufacturing
    • Diseases
      • Cardiovascular
      • Central Nervous System
      • Immunology
      • Infectious Diseases
      • Oncology
  • Deals
  • US Election
  • Disruption
  • Coronavirus
Partners
  • Accelerating Clinical Trials
  • Powder Handling
  • Simplifying Clinical Trials
Tools
  • Companies
    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos
  • Reports
  • Awards
  • Events
  • Magazine
The Company
  • About Us
  • Contact Us
  • Advertise With Us
  • Visit GlobalData
  • Login
  • Register
  • Login
  • Register
Diseases Immunology

Sections

  • Clinical Trials
  • Supply Chain
  • Drug Development
  • Manufacturing
  • Diseases
    • Cardiovascular
    • Central Nervous System
    • Immunology
    • Infectious Diseases
    • Oncology
    • Respiratory

Most Read

  • AstraZeneca to acquire biopharmaceutical firm Alexion for $39bn
  • The rise of gout: examining drug development for an age-old disease
  • Sanofi signs agreement to acquire Kiadis Pharma for $359m

Most Recent

deal

AstraZeneca to acquire biopharmaceutical firm Alexion for $39bn

14 Dec 2020
Latest Immunology
  • AstraZeneca to acquire biopharmaceutical firm Alexion for $39bn
    1 month
  • The rise of gout: examining drug development for an age-old disease
    2 months
  • Sanofi signs agreement to acquire Kiadis Pharma for $359m
    3 months
  • Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19
    9 months
  • AstraZeneca to acquire biopharmaceutical firm Alexion for $39bn
    1 month
  • The rise of gout: examining drug development for an age-old disease
    2 months
  • Sanofi signs agreement to acquire Kiadis Pharma for $359m
    3 months
  • Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19
    9 months
AstraZeneca to acquire biopharmaceutical firm Alexion for $39bn
deal

AstraZeneca to acquire biopharmaceutical firm Alexion for $39bn

AstraZeneca has signed a definitive agreement to acquire global biopharmaceutical company Alexion Pharmaceuticals for $39bn or $175 a share. According…

14 Dec 2020

Top 5 Most Read

Analysis 2 hours

Enter Amazon Pharmacy: the beginning of a great online pharmacy fight?

1
Sponsored 3 days

A standard approach to drug development for accessing the globe

2
Analysis 4 days

Genomics and Covid-19: UK’s real-time surveillance system to track viral mutations

3
Analysis 5 days

Disease-cancelling drugs: Immuneering raises $62m in Series B round

4
Analysis 6 days

Biopharma M&A: EY analysts optimistic for 2021 deals after a mixed 2020

5

Join Our Newsletter

Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Join Our Newsletter

Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Company A-Z

View All

Company Releases

View All

White Papers

View All

Videos

View All
logo-horizontal

Powered by Pharma Tech Logo

  • About Us
  • Editorial Approach
  • Contact Us
  • Terms & Conditions
  • Privacy Policy

© Copyright 2021 Verdict Media Limited.

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more